Last updated: 2026-09-06 05:28:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tectonic Therapeutic, Inc. (TECX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $30,90, with a market capitalization of $593,91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14,39 to $39,53. This page covers its latest market performance, valuation, price trends and company information.
$593,91M | |
$29,85 | |
$61,07 | |
$13,70 | |
$29,92 | |
142,89K | |
-- | |
-- | |
$39,53 | |
$14,39 | |
-- | |
-- |
Tectonic Therapeutic, Inc. (TECX) last closed at $29,92 as of 2026-09-04 23:31:00, unchanged from the previous close of $29,92.
During the latest regular trading session, TECX traded between $13,70 and $61,07, with a volume of 142,89K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Tectonic Therapeutic, Inc. (TECX) moved from $35,67 to $30,90, representing a decline of 13,37% ($4,77).
The stock traded between $29,75 and $31,16 during the period. The latest price is near the upper end of the 7-day range, indicating strong downward.
The average daily volume was 266,18 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 65,7%
TECX is currently trading at $30,90, placing it 65,7% of the way from its 52-week low of $14,39 to its 52-week high of $39,53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 60 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tectonic Therapeutic, Inc. (TECX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.